Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
about
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesionsKinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFPLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cellsDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityBRAF Mutation in Hairy Cell LeukemiaResistance to BRAF inhibitors: unraveling mechanisms and future treatment optionsThe Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF KinaseInhibitors that stabilize a closed RAF kinase domain conformation induce dimerizationPyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsNovel small molecule Raf kinase inhibitors for targeted cancer therapeuticsModification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinaseNCI-60 whole exome sequencing and pharmacological CellMiner analysesRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsThe B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor modelsAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFMolecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cellsIdentification of BRAF inhibitors through in silico screeningAn in silico study of the molecular basis of B-RAF activation and conformational stability.Characterization and performance of nucleic acid nanoparticles combined with protamine and gold.A proposal: a comprehensive platform to characterize tumors in Chinese and improve success in cancer drug discovery and development.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition.VDA, a method of choosing a better algorithm with fewer validationsA physicochemical descriptor-based scoring scheme for effective and rapid filtering of kinase-like chemical space.Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.Finding undetected protein associations in cell signaling by belief propagation.Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanomaPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionA switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.A MEK-independent role for CRAF in mitosis and tumor progression.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.The current state of targeted therapy in melanoma: this time it's personalRaf kinases: function, regulation and role in human cancer.
P2860
Q21004109-5AE8C649-BB25-4A65-83F3-95B63A5F05BAQ24298749-CF3A8DE2-C318-4BC7-9A86-8A5D924FF38BQ24606438-09E585E2-5829-41F7-8D35-234AB7B70EDBQ24652600-15523D9C-62CC-453F-8B0D-B9DA96334338Q27014016-7807AAB4-01C0-4B5D-940A-36317FDB33AEQ27023596-72DAE501-7127-4F0C-B657-E4CA6433C134Q27654846-43C331CE-1917-43F6-BB11-835BE7D183DEQ27678182-14F0EEE4-8D05-4519-BF02-A45924AF717DQ27684109-CBB7C42B-CCD1-43B7-B51F-BCE4ED7C9814Q28265862-10FA546A-D304-4AE6-9BBD-11FDAEB2B071Q28538778-29C0C47D-BB2A-4F46-AC0D-9F54F06A1F8CQ28540834-F06F264D-BD0D-425E-80C9-52F245B1A11FQ28730438-F14D2BAC-936E-4F50-90FF-59B25B14F7F1Q28744228-CE0C425F-A899-4C45-A2C6-D478A54E2B52Q29614757-2D793100-8815-4BCE-98CA-9D4FB385E821Q29616828-543A2243-E985-4F72-9A0A-9A61E4A22AE0Q30391310-36C688CB-FAE7-41BB-A438-966BB8045FE2Q30395364-E57CF011-6DCC-4484-A30C-9A34B23DC2CCQ31012806-CDD7F9F8-D060-49EA-A190-330ED42EB66DQ33368383-4CC77C48-0992-4167-888B-E4857C3582E3Q33485591-C46F1F55-C16F-45E4-955F-74AC0BFFEA57Q33499568-CD0D5CD7-7916-4417-9E39-E235C86B913BQ33579695-B97678FF-7515-4909-98E4-B5D4CA12D921Q33906093-FD59C209-2C9C-4554-A45C-B915B829752DQ33996875-0E60327B-45AF-4AA6-AC69-C390646C4015Q34064348-B692637B-A971-48E9-8D05-96D250647AEEQ34153687-FF195A2A-428B-4D9C-9DF1-63700E9A08B8Q34207363-1A1515B5-4AB5-4770-90D8-0294D91D54B2Q34225871-6A1F6816-207D-44BD-A6ED-AF2FAE9F5EEDQ34333456-C2B146EA-04F8-4D9A-B152-DE4DF717C71AQ34402062-5C9D3771-D9C0-45D8-BE09-BE11E144415AQ34490371-56BD8923-03DF-415E-A071-BD4385E6CEF0Q34662736-D60C738F-3D9C-4E75-8DEB-442F7D1878FDQ34669746-1786B6D0-D6CA-458A-9BC1-BE334BFC28DDQ34761941-7435FB1C-130D-4B51-BEA7-9043BEBFFFBAQ35233178-293B5A57-51AF-45C2-B2C5-B9D9CEB0B016Q35600821-282D4722-51D6-4561-8D7E-105265BC5CC4Q35679353-1348F1E9-4874-4A33-9383-CA1B72989E4CQ35878248-6DB7F7E6-DC6A-4AD3-9996-74F33BCFB622Q36002845-9773AB73-D4A7-4F4C-BE90-21C7DD961773
P2860
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@ast
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@en
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@nl
type
label
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@ast
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@en
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@nl
prefLabel
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@ast
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@en
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@nl
P2093
P50
P1433
P1476
Demonstration of a genetic the ...... the kinase inhibitor SB-590885
@en
P2093
Alastair J King
Ami S Lakdawala
Andrew K Takle
Cynthia M Rominger
David Chau
David M Wilson
David W Rusnak
Denis R Patrick
Earl W May
Erin Hugger
P304
11100-11105
P356
10.1158/0008-5472.CAN-06-2554
P407
P577
2006-12-01T00:00:00Z